I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $406.25M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Adenosine |
Charlottesville, |
1/25/05 | $3.5 |
Details on the financing were not disclosed |
Alexza |
Palo Alto, | 1/6/05 |
$52 |
Alloy Ventures and Delphi Ventures co-led the Series D financing, which included Abingworth Bioventures, MDS Capital, Pacific Rim Ventures, T. Rowe Price, WestRiver Capital, Alejandro Zaffaroni, Frazier Healthcare, Versant Ventures, 5AM Ventures, Burrill & Co., CMEA Ventures, New Enterprise Associates and Zesiger Capital Group |
Apoxis SA | Lausanne, | 1/25/05 |
€15 | Participating in the second-round financing were Novo Nordisk, Banexi Ventures Partners, HealthCap and private investors |
Biolipox AB |
Stockholm, | 1/10/05 |
$41 |
The Series C round was led by Scandinavian Life Science Venture and included existing investors HealthCap, Apax Partners, Sofinnova Partners, Auriga Partners and Crédit Lyonnais Private Equity |
BioWisdom |
Cambridge, | 1/31/05 |
£2.3 |
New investors Finsbury Life Sciences Investment Trust and NIF Ventures Ltd. were joined by returning investors, including Merlin Biosciences and MB Venture Capital, in the financing round |
Chelsea |
Charlotte, | 1/11/05 |
$14.5 |
The company sold Series A convertible preferred stock in the round; Paramount BioCapital Inc. was placement agent |
Compound |
Waltham, | 1/18/05 |
$15.5 |
The company raised $15.5M in an expansion of its Series A financing; it raised $12M in May 2003; investors included Atlas Venture, Flagship Ventures and Polaris Venture Partners |
DanioLabs |
Cambridge, | 1/17/05 |
£3.2 |
Cambridge Gateway Fund led the first-round financing, which also included Merifin, NVM and existing and new angel investors |
Efficas Inc. |
Boulder, Colo. | 1/4/05 |
$3 |
The Series A-3 round was led by the Bay Area Equity Fund and included Boston Life Science Venture Corp.; total investment in the company is about $8.5M |
Elbion AG |
Dresden, | 1/10/05 |
€25 |
The Degussa AG spinout completed a first-round financing co-led by 3i, Burrill & Co. and DVC Deutsche Venture Capital; other investors were AGF Private Equity, Quintiles PharmaBio Development, BayTech Venture Capital and Marubeni Corp. |
Immutep SA |
Orsay, | 1/10/05 |
€2.5 |
Innoven Partenaires led the second-round financing, which included an investment from Equitis'H2I fund |
Nereus |
San Diego | 1/4/05 |
$24.3 |
New investors HBM BioVentures Ltd. and HBM BioCapital LP led the Series D preferred round, expected to be the first tranche of a $42.6M deal; other investors were Advent International, InterWest Partners, Genavent Partners, Red Abbey Venture Partners, Alta Partners, Forward Ventures, GIMV, Novartis Bioventure Fund, Pacific Venture Group, FirstBio and Lotus BioScience Ventures |
Neuro3d |
Mulhouse, | 1/3/05 |
€34.5 |
Gilde Investment Management's Biotech fund and AXA Private Equity led the Series C financing, which also included Healthcare Private Equity LP, GIMV, HealthCap, Techno Venture Management Partners, Sofinnova Partners and APAX Partners |
OctoPlus |
Leiden, the | 1/20/05 |
$23.85 |
The second-round financing was led by Life Sciences Partners II BV and S.R. One Ltd., and included Innoven Partenaires, Fortis Private Equity and SurModics Inc.; Fortis Bank was placement agent |
OpGen Inc. |
Madison, | 1/24/05 |
$5 |
The company completed a Series B round of financing; investors included Mason Wells Biomedical Fund, Stonehenge Capital, The State of Wisconsin Investment Board and The Wisconsin Alumni Research Foundation |
Paradigm |
Cambridge, | 1/7/05 |
£5.5 |
Bio*1Capital, Merlin Biosciences and Avlar BioVentures invested additional money in the company following its acquisition of Amedis Pharmaceuticals Ltd. |
Pennsylvania |
Philadelphia | 1/25/05 |
$3.5 |
BioAdvance is providing a total of $3.5M in seed capital to the following companies: Avid Radiopharmaceuticals, Marillion Pharmaceuticals, InfraScan, Galleon Pharmaceuticals, Jerin Discovery, Melior Discovery and SansRosa Pharmaceuticals |
PolyMedix |
Philadelphia | 1/5/05 |
$6 |
The company had two closings in a Series Bfinancing round; details were not disclosed |
Predix |
Woburn, Mass. | 1/25/05 |
$43 |
The Series C financing round was led by Forward Ventures, Boston Millennia Partners and CMEA Ventures, and included new investors Novel Bioventures, Yamanouchi Venture Capital, Yasuda and JAFCO Ventures and previous investors OrbiMed Advisors LLC, S.R. One, Yozma Group, International Life Science Partners and PA Consulting |
Protalix |
Karmiel, Israel | 1/12/05 |
$1.3 |
The funding was provided by investment fund Pontifax, which has an option to invest another $1M |
Spaltudaq |
Seattle | 1/24/05 |
ND |
The company, started by Accelerator Corp., completed a Series A financing that included MPM Capital, ARCH Venture Partners, Amgen Ventures, OVP Venture Partners, Versant Ventures and Alexandria Real Estate Equities |
VirtualScopics |
Rochester, | 1/6/05 |
$1.4 |
An affiliate of Loeb Partners Corp. exercised all the warrants it received in its initial investment in VirtualScopics |
Vitae |
Fort | 1/4/05 |
$34 |
New investors Atlas Venture and Wellcome Trust joined existing investors Prospect Venture Partners, Venrock Associates and New Enterprise Associates in the financing round |
Zealand |
Glostrup, | 1/7/05 |
€13.3 |
BankInvest led the financing round, which also included LD Pension, Dansk Erhvervsinvestering and Vaekstfonden |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $51.96M | ||||
Company |
Partner | Amt. |
Triggering | Details (Date) |
Abgenix Inc. |
Amgen Inc. | ND |
Milestone |
Triggered by Amgen's advancement into (ABGX) clinical trials of an undisclosed antibody created using Abgenix's XenoMouse technology(1/13) |
Abgenix Inc. |
Chiron Corp. | ND |
Milestone |
Triggered by Chiron's filing of an IND for a fully human antibody, CHIR-12.12, targeting CD40 that was created using Abgenix's Xeno-Mouse technology (1/12) |
Abgenix Inc. |
Human Genome | ND |
Milestone |
Triggered by HGS' filing of an IND for a fully human antibody to the CCR5 receptor created using Abgenix's XenoMouse technology (1/10) |
Alnylam |
Merck | $7 |
Milestone |
$5M of the payment was made in stock and $2M in cash; it was triggered by development of in vivo RNAi technology to a prespecified level of performance (1/3) |
ArQule Inc. |
Wyeth | ND |
Milestone |
Payments were triggered by Wyeth beginning development of a compound for Alzheimer's disease, and for progress on a compound for rheumatoid arthritis (1/10) |
Avant Immuno- |
Glaxo | $2 |
Milestone |
The acceptance for review by European regulatory authorities of a marketing application for the Rotarix rotavirus vaccine triggered the milestone (1/6) |
Galapagos |
Boehringer | ND |
Milestone |
BI licensed targets in viral replication that were discovered using Galapagos' Silence-Select gene knockdown platform (1/20) |
Karo Bio |
Merck & | ND |
Milestone |
Triggered by initiation of clinical trials for the most advanced compound from their collaboration focused on estrogen receptors (1/21) |
NeuroSearch |
Boehringer | $5 |
Milestone |
Triggered by continued development of NS2330 for treating Alzheimer's and Parkinson's diseases; it is in Phase II trials (1/24) |
Novogen |
Solae LLC | $0.86 |
Milestone |
The milestone was paid as part of its license to certain Novogen soy isoflavone technology (1/18) |
Pharmos |
Bausch & | $12.1 |
Milestone |
Triggered by B&L's launch of Zylet, which was part of the loteprednol etabonate business Pharmos sold to B&L in 2001 (1/23) |
Regeneron |
Sanofi- | $25 |
Milestone |
The payment was made in connection with clinical development of VEGF Trap in cancer indications (1/10) |
Vernalis plc |
Serono SA | ND |
Milestone | Triggered by Serono's initiation of a Phase I trial of their selective inhibitor of MMP-12, which is being developed for inflammatory diseases (1/19) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Private company. |
||||
Currency conversions are based on exchange rates at the time of the deal. |
||||
ND = Not disclosed. |
||||
CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange. |
||||
